Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2013-06-27
Target enrollment:
Participant gender:
Summary
This is a Phase I study, which means that the goal is to see if the combination of
Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a
standard treatment for Hepatocellular Carcinoma. Temsirolimus is used to treat cancer in the
kidneys. It is hoped that the addition of Temsirolimus will make Sorafenib more effective
against Advanced Hepatocellular Carcinoma, however this can not be guaranteed. The addition
of Temsirolimus to Sorafenib is not an FDA approved treatment for Advanced Hepatocellular
cancer.